Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma

Lisa Derosa; Hassane Izzedine; Laurence Albiges; Bernard Escudier

doi:10.4081/oncol.2016.298

Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma

Lisa Derosa, Hassane Izzedine, Laurence Albiges, Bernard Escudier

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

20 Citations (Scopus)

Résumé

Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.

langue originale	Anglais
Pages (de - à)	54-59
Nombre de pages	6
journal	Oncology Reviews
Volume	10
Numéro de publication	2
Les DOIs	https://doi.org/10.4081/oncol.2016.298
état	Publié - 1 janv. 2016

Accès au document

10.4081/oncol.2016.298

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{38cf09eff27f463ba6c773f6e7d41560,

title = "Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma",

abstract = "Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.",

keywords = "Angiotensin system inhibitors, Hypertension, Renal cell carcinoma, Renin-angiotensin system",

author = "Lisa Derosa and Hassane Izzedine and Laurence Albiges and Bernard Escudier",

note = "Publisher Copyright: {\textcopyright} 2016 Copyright L. Derosa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2016",

month = jan,

day = "1",

doi = "10.4081/oncol.2016.298",

language = "English",

volume = "10",

pages = "54--59",

journal = "Oncology Reviews",

issn = "1970-5557",

number = "2",

}

TY - JOUR

T1 - Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma

AU - Derosa, Lisa

AU - Izzedine, Hassane

AU - Albiges, Laurence

AU - Escudier, Bernard

N1 - Publisher Copyright: © 2016 Copyright L. Derosa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.

AB - Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies. The aim of this review is to discuss the available treatment options for mRCC and associated incidence of hypertension as well as summarize the known data about ASIs use and mRCC. Additionally, given that the optimal management of HTN remains unclear, we will focus on prevention strategies and propose potential therapeutic approaches.

KW - Angiotensin system inhibitors

KW - Hypertension

KW - Renal cell carcinoma

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=85002634099&partnerID=8YFLogxK

U2 - 10.4081/oncol.2016.298

DO - 10.4081/oncol.2016.298

M3 - Article

AN - SCOPUS:85002634099

SN - 1970-5557

VL - 10

SP - 54

EP - 59

JO - Oncology Reviews

JF - Oncology Reviews

IS - 2

ER -